ADAR2 Polyclonal Antibody | anti-ADAR2 antibody

ADAR2 Polyclonal Antibody

Cat. Num. AAA8521100

• Gene Names: ADARB1; RED1; ADAR2; DRABA2; DRADA2
• Synonyms: ADAR2; Polyclonal Antibody; ADAR2 Polyclonal Antibody; anti-ADAR2 antibody

• Clonality: Polyclonal
• Sequence Length: 701

NCBI and Uniprot Product Information

• NCBI GI #: 4501919
• NCBI GeneID: 104
• NCBI Accession #: NP_001103.1
• NCBI GenBank Nucleotide #: NM_001112.3
• UniProt Accession #: P78563; O00395; O00465; O00691; O00692; P78555; A6NFK8; A6NJ84; C3TTQ1; C3TTQ2; C9JUP4; G5E9B4
• Molecular Weight: 73,665 Da
• NCBI Official Full Name: double-stranded RNA-specific editase 1 isoform 1
• NCBI Official Synonym Full Names: adenosine deaminase, RNA specific B1
• NCBI Official Symbol: ADARB1
• NCBI Official Synonym Symbols: RED1; ADAR2; DRABA2; DRADA2
• NCBI Protein Information: double-stranded RNA-specific editase 1
• UniProt Protein Name: Double-stranded RNA-specific editase 1
• UniProt Gene Name: ADARB1
• UniProt Synonym Gene Names: ADAR2; DRADA2; RED1

NCBI Description

This gene encodes the enzyme responsible for pre-mRNA editing of the glutamate receptor subunit B by site-specific deamination of adenosines. Studies in rat found that this enzyme acted on its own pre-mRNA molecules to convert an AA dinucleotide to an AI dinucleotide which resulted in a new splice site. Alternative splicing of this gene results in several transcript variants, some of which have been characterized by the presence or absence of an ALU cassette insert and a short or long C-terminal region. [provided by RefSeq, Jul 2008]

Uniprot Description

Catalyzes the hydrolytic deamination of adenosine to inosine in double-stranded RNA (dsRNA) referred to as A-to-I RNA editing. This may affect gene expression and function in a number of ways that include mRNA translation by changing codons and hence the amino acid sequence of proteins; pre-mRNA splicing by altering splice site recognition sequences; RNA stability by changing sequences involved in nuclease recognition; genetic stability in the case of RNA virus genomes by changing sequences during viral RNA replication; and RNA structure-dependent activities such as microRNA production or targeting or protein-RNA interactions. Can edit both viral and cellular RNAs and can edit RNAs at multiple sites (hyper-editing) or at specific sites (site-specific editing). Its cellular RNA substrates include: bladder cancer-associated protein (BLCAP), neurotransmitter receptors for glutamate (GRIA2 and GRIK2) and serotonin (HTR2C), GABA receptor (GABRA3) and potassium voltage-gated channel (KCNA1). Site-specific RNA editing of transcripts encoding these proteins results in amino acid substitutions which consequently alter their functional activities. Edits GRIA2 at both the Q/R and R/G sites efficiently but converts the adenosine in hotspot1 much less efficiently. Can exert a proviral effect towards human immunodeficiency virus type 1 (HIV-1) and enhances its replication via both an editing-dependent and editing-independent mechanism. The former involves editing of adenosines in the 5'UTR while the latter occurs via suppression of EIF2AK2/PKR activation and function. Can inhibit cell proliferation and migration and can stimulate exocytosis.